Multiple Screens One Computer (CTS)

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday Feb. 09, 2010

DrStockPick.com Stock Report!

**************************************************************

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.

** PWRM reported that 4 abstracts covering results from clinical validation trials of the NuroPro(R) AD test for Alzheimer’s disease were submitted to the 2010 annual meeting of the International Congress of Alzheimer’s Disease, taking place July 2010. The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from “normal” individuals and patients with other neurological disorders. The test, developed by Power3, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer’s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.

The four studies present the capabilities of NuroPro for accurate diagnosis, targeted therapy and drug response monitoring. They involve a total of 154 Alzheimer’s disease and 91 Parkinson’s disease patients, 210 age-matched normal and 173 disease control individuals. The abstracts report the combined results from the clinical validation trials of the NuroPro(R) AD and NuroPro PD tests, conducted by the PWRM scientific team, led by medical director Lourdes R. Bosquez, MD and chief scientific officer, Ira L. Goldknopf, Ph.D., in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute, Sun City, Arizona, Katerina Markopoulou, M.D., Assistant Professor of Neurology at the University of Thessaly, Larissa Greece, along with previous studies Power3 conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology, Baylor College of Medicine, Houston TX. Dr. Appel is now Co-Director of the Methodist Neurological Research Institute, Houston, TX, and continues to be chairman of the scientific advisory board of Power3.

More about PWRM at www.Power3Medical.com

**************************************************************

AMGN, Amgen Inc.

AMGN discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.

AMGN announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and reducing the rate of multiple SREs (hazard ratio 0.82, 95 percent CI: 0.71, 0.94). Both results were statistically significant.

More about AMGN at www.amgen.com

**************************************************************

Keep a close eye on PWRM and AMGN, do your homework, and like always BE READY for the ACTION!

**************************************************************

**************************************************************

***********Advertisement***********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

_______________________________________________________

_______________________________________________________

Dr. Stock Pick is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1400 websites www.crwenews.com, www.stock-ir.com, www.PennyOmega.com, www.PennyToBuck.com, www.BestOTC.com, www.stock-pr.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com

 

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday Dec. 31, 2009

DrStockPick.com Stock Report!

**************************************************************

CRWENews Stock Highlights for 2010

The experts predict the coming year will be a rocky one for investors.

With the subprime meltdown, sky-high oil, and a looming economic downturn, they might be right.

None the less, in my eyes the truth is; investors face major challenges every year. Yet a select few manage to overcome these obstacles, beat the market, and build lasting wealth.

As an advocate of the here and now, I suggest that a better idea is to take this opportunity to refocus—your attention, your effort and your intention. I’m not talking New Year’s resolutions or anything so trendy. No, it is time to drag out the thoughts you’ve had on your investment strategy and take a hard look at the current realities in the world of investment and get everything up to date and make it happen.

Example: In January of this year when everything was gloomy, we decided to post 21 publicly traded companies on CRWENews.com which we thought you should keep an eye on. Below you will see each company we selected and its related share price activity chart for the year.

After viewing them personally, I smiled. Afterwards, we had some thought into our next year’s stock to watch selections. The results were to continue with our same twenty-one “2009 stocks to watch choices throughout 2010 as well.

After our decision in reference to which stocks to watch for 2010, we felt inspired to share them with you as you put some thought into your 2010 investment strategy.

If you should forget the below picks, you may always go to “htpp://www.crwenews.com” and view them. They are located within the right column of the home page near the bottom of the page.

By the way, from the staff of CRWENEWS (Crown Equity Holdings, Inc.)

Happy New Year and think positive!

CRWE,QCOM,CSCO

IBM,GS,GOOG

BAC,YHOO,INTC

JPM,NYX,WFC

AMGN,ORCL,MSFT

CBI,KLAC,EMC

TXN,ADBE,PWRM

***********Advertisement***********

******************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) . Rule 17B requires disclosure of payment for investor relations.

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMGN, PWRM, JNJ, CSRH, GE, CVAT, TEVA, AQNM

**************************************************************

AMGN, Amgen Inc.

AMGN, a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.

The Food and Drug Administration wants more information about AMGN’s osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009

Further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”

More about PWRM at www.power3medical.com

**************************************************************

CSRH, Consorteum Holdings Inc, CSRH.OB

CSRH has launched its mobile check cashing program. The introduction of this service will offer those that are currently using check cashing facilities a much more convenient way to cash their payroll checks. After two years of development with its partners, Consorteum has now proceeded to the pilot phase of its check cashing program in the Toronto, Ontario region. The first stage of the pilot implementation will be the deployment of this new service on several trucks. The drivers will be able to offer their clients the convenience of real-time check cashing services and load customer funds directly onto a personalized prepaid Credit Card right at the mobile truck’s location.

Quent Rickerby, President & COO of CSRH, said, “Consorteum has been very eager to deploy this program and sees significant growth and opportunity within the check cashing industry. Not only are we bringing the convenience of a check cashing service to the customer directly, but we’re also mitigating the overhead costs of a brick-and-mortar store front.”

CSRH will charge the customer a percentage of the value of the check as a convenience fee for processing the transaction. It is expected the program will be fully deployed across other regions of Ontario in early 2010 and generate significant transactional volumes for the company within a year. The program is expected to expand into several U.S. regions in late 2010.

Rickerby went on to say, “Today there are approximately 13,000 check cashing stores in the United States which collectively process $80 Billion worth of checks annually. The average payroll check today is anywhere from $500 to $600 each. With such a large market to capitalize, we anticipate the launch of this program to substantially increase our revenues as well as shareholder value.”

More about CSRH at www.consorteum.com

**************************************************************

JNJ, Johnson & Johnson

JNJ engages in the research and development, manufacture, and sale of various products in the health care field worldwide.

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

**************************************************************

CVAT, Cavitation Technologies Inc, CVAT.OB

CVAT is a “Green-Tech” company, established in 2006 to become a world leader in the development of new cutting edge technologies for the vegetable oil refining, renewable fuel, petroleum, water treatment, wastewater sanitation, food and beverage, and chemical industries.

CVAT has signed Miura Engineering Co., Ltd. Tokyo, Japan (”MEC”) (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East.

According to Kirk Wiggins, CTI’s Director of Sales and Business Development, “We are very pleased to be working with Miura Engineering Co., Ltd. and Mr. Shigeru Miura, President of the company. Mr. Kazushi Miyauchi, General Manager for MEC visited us recently at our headquarters in Chatsworth, California and the discussions were very productive.” Mr. Miyauchi has stated, “We agree that our two companies will find many areas where we can work together for our mutual success.” Mr. Koichi Takahagi, General Manager, Engineering Department, has also stated “Miura Engineering Co. is very pleased to work with CTI and to offer their technology to our customers in Japan and Korea.”

Mr. Wiggins further stated, “The exciting thing about CTI is the diverse applications of our technologies. All of our applications are in industries where there are significant environmental problems and/or a need to reduce costs and improving profitability. We are working on projects and technologies for vegetable oil refining, renewable fuels, petroleum, water desalination, wastewater treatment, food and beverage, chemical industries.” Miura Engineering has experience in many of these areas and we expect that we will be very successful working with them.

Roman Gordon, CTI CEO, stated, “We have many companies wanting to represent us but we are very selective. After discussions with Mr. Kazushi Miyauchi we are now very confident in them and that we will do many good things together. We are pleased to have them on our team.”

More about CVAT at www.cavitationtechnologies.com

**************************************************************

GE, General Electric Co.

GE Money’s Sales Finance unit, based in Kettering, Ohio, is a part of General Electric Company’s GE Capital division, (NYSE: GE - News). GE Money provides credit card programs and financial services for consumers through dealers; national, regional and independent retailers; associations; contractors; manufacturers; healthcare practices; and service providers in nearly 20 industries including: automotive, consumer electronics and appliances, elective health care, floor covering, home design and improvement, home furnishings, jewelry, music, powersports, outdoor power equipment and sporting goods.

GE Money announced a multi-year agreement to offer consumer financing. The Lumber Liquidators credit card offers consumers a no annual fee card with special financing options and 0nline account management. The card is managed by GE Money’s Sales Finance unit, which provides billions of dollars of consumer financing through more than 145,000 small business locations on Main Streets across the United States.

**************************************************************

AQNM, Aquentium, Inc., AQNM.OB

Aquentium is a diversified company with an emphasis on green technologies. The company currently has interests in non-chemical sanitation equipment, alternative energy, waste-to-energy, water treatment, food safety, mining, building materials, affordable housing, re-deployable emergency housing, and recycling.

Aquentium Announces Distributorship Opportunities for Its Ozone Sanitation and Water Treatment Equipment for the Country of India

Aquentium, Inc. (OTCBB: AQNM) a publicly traded company with a focus on “green technologies” announced recently that the company is now offering distributorship opportunities for its complete line of ozone sanitation and water treatment equipment for the Country of India.

India is the seventh-largest country by geographical area, the second-most populous country, and the most populous democracy in the world. India is a republic consisting of 28 states and seven union territories with a parliamentary system of democracy.

India has the world’s twelfth largest economy at market exchange rates and the fourth largest in purchasing power. Economic reforms since 1991 have transformed it into one of the fastest growing economies; however, the country still suffers from high levels of disease and malnutrition.

The uniqueness of the Aquentium equipment is that ozone is over 50% more effective than chemicals and over 3,000 times faster acting than chemicals. Ultimately, Aquentium believes that we have better technology to combat e-coli, salmonella, listeria and other bacteria or viruses.

Aquentium Announces High Speed Ozone Hand Dryer for Increased Bathroom Sanitation and Bacteria and Virus Protection

Aquentium, Inc. (OTCBB: AQNM) a publicly traded company with a focus on “green technologies” is pleased to announce their high speed ozone hand dryer as a solution for increased bathroom sanitation and bacteria and virus protection. The hand dryer combines high speed drying with ozone in order to sanitize the air and keep the blowers inside the dryer free from bacteria.

Traditionally, businesses have used paper towels or ordinary slow speed hand dryers for people wanting to dry their hands. The Aquentium hand dryer installed at any restaurant, hotel, medical facility, school, gas station or other location should allow for cost savings and as well as provide an environmental friendly technology.

Independent studies show that millions of Americans are becoming more concerned about their exposure to bacteria and viruses in public areas, such as fast food restaurants, restrooms, and convenience stores.

Aquentium offers the finest solution for companies seeking to reduce the costs for bathroom paper towels. Aquentium’s hand dryer not only saves money for businesses, but also helps save the environment.

The Aquentium hand dryer can significantly reduce costs by eliminating expensive paper towel consumption. Companies and organizations no longer have to deal with the hassle of ordering paper towels, paying for the expense of product delivery, and replacing paper towels. The Aquentium hand dryer also eliminates waste and contamination from dirty towels, and lowers trash removal expense and labor costs.

Since the Aquentium hand dryer contains multiple high speed blowers, it creates a more encircling airflow, which speeds drying time and system operation. Simply place your hands under the dryer and it activates automatically. The hand dryer shuts off automatically once your hands are removed. This means reduced electrical costs.

Most hand dryers have filters that build up with mold and bacteria, especially in high-humidity restrooms. However, the Aquentium hand dryer can effectively sanitize itself. You no longer have to worry about re-infecting people’s hands with a non-maintenanced, old-style hand dryer.

“Our hand dryer is designed to help keep people’s hands sanitized. With high speed blowers, your hands dry quickly and efficiently,” stated Aquentium CEO Mark Taggatz.

**************************************************************

TEVA, Teva Pharmaceutical Industries Limited

TEVA engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients worldwide.

TEVA sues Mylan on generic Copaxone

**************************************************************

Keep a close eye on AMGN, PWRM, JNJ, CSRH, GE, CVAT, TEVA and AQNM do your homework, and like always BE READY for the ACTION!

***********Advertisement***********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and expects to receive an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand shares of free trading stock from a third party for advertising services for Cavitation Technologies, Inc. (CVAT.OB) and an additional twenty-five thousand shares of 144 restricted stock from Cavitation Technologies, Inc. (CVAT.OB) for 12 months of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from Consorteum Holdings Inc. for 30 days of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received 78,000 free trading and 500,000 144 (restricted) shares from a third party for 6 months of advertising services for Consorteum Holdings Inc, (CSRH.OB). Crown Equity Holdings has been paid 100,000 restricterd shares of Aquentium for advertising services. Crown Equity Holdings has been paid 100,000 restricterd shares of Aquentium for advertising services.

_______________________________________________________

_______________________________________________________

Dr. Stock Pick

is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1000 websites www.crwenews.com, www.stock-ir.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com

 

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

PWRM, Power 3 Medical Products Inc, PWRM.OB

AMGN, Amgen Inc.

**************************************************************

Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

- Power3 Medical Products, Inc. a Leader in Neurodegenerative Disease and Cancer Diagnostic Biomarkers Announces its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009 -

Power3 Medical Products, Inc. (OTC BB: PWRM), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

Power3 Medical Products announced today further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”

In his Keynote address, entitled “Principles of Omic Medicine Applied to Differential Diagnosis - Breast Cancer and Neurodegenerative Diseases,” Dr. Goldknopf will discuss the “necessary fundamental principles” that BC-SeraPro™ and NuroPro® exemplify which enable the company’s biomarkers and tests to “more effectively address the unmet clinical needs that challenge us today.” He will describe the company’s unique position and ability to use biomarkers for testing in personalized medicine and the various facets that are required for discovery, validation and to commercialize a group of biomarkers.

“For physicians to order a test for a patient, they first need to believe in it. That takes major international scientific acceptance and publication in peer reviewed journals. This meeting is an excellent opportunity to showcase world-wide the strides we have made through refinements in our biomarkers and blood test for early stage detection of breast cancer (BC-SeraPro, GLOBE NEWSWIRE Aug. 20, 2009)” said Dr. Goldknopf. “Earlier presentations on Alzheimer’s and Parkinson’s disease biomarkers and tests were given at the annual meetings of the American Academy of Neurology in Seattle and the International Congress of Alzheimer’s Disease in Vienna (NuroPro, World Stock Wire July 14, 2009). We recently published the Parkinson’s disease biomarkers and test results in Biochemical and Biophysical Research Communications (Reuters Sept 2, 2009), and more publications are in the works.”

“We are extremely proud and excited about the recognition of Dr. Goldknopf and Power3 by the opportunity to chair this session and present at this international meeting.” said Ms Park, Power3’s CEO. “Dr. Goldknopf is the Keynote speaker and will feature new progress in clinical validation of the company’s biomarkers and blood test for early stage diagnosis of Breast cancer leading to commercialization.”

**************************************************************

Amgen Inc. to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress

- Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented -

Amgen Inc. (AMGN) discovers, develops, manufactures and delivers innovative human therapeutics. AMGN was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.

AMGN today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa® (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the ‘136′ study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the ‘244′ study).

Detailed data will also be presented from two Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first-line and second-line treatment of metastatic colorectal cancer (the ‘203′ and ‘181′ trials, respectively).

“Amgen is very pleased to be presenting these important data from the denosumab and Vectibix development programs,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “The data from these trials demonstrate that both denosumab and Vectibix have the potential to improve outcomes in patients suffering from cancer.”

**************************************************************

Keep a close eye on PWRM and AMGN today, do your homework, and like always BE READY for the ACTION!

***********Advertisement***********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website for Power 3 Medical Products Inc. (PWRM.OB)

_______________________________________________________

_______________________________________________________

Dr. Stock Pick

is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1400 websites like www.crwenews.com, www.stock-ir.com www.pennyomega.com, www.stock-pr.com, www.bestotc.com, giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com

 

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

AMGN, Amgen Inc.

GLW, Corning Inc.

HRAL, HearAtLast Holdings Inc, HRAL.PK

DrStockPick Watch List!

DrStockPick Watch List! for Monday July 27, 2009

 

My Picks for Monday July 27, 2009 are:

**************************************************************

AMGN, Amgen Inc.

AMGN is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine.

AMGN pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

AMGN is forecast to post second-quarter earnings of $1.16 a share

**************************************************************

HRAL, HearAtLast Holdings Inc, HRAL.PK

HRAL is a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market.

HRAL is a Nevada corporation that owns and operates its wholly-owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada.

With a high concentration of laborers and retirees, the percentage of noise-induced patients is significant and many benefit from Canada’s world leading health care system and workman’s compensation programs. Noise induced hearing loss is recognized as the number one disability facing the North America workforce claims the World Health Organization (WHO; http://www.who.int) at a cost of over 60 billion dollars annually. Even after many years of OSHA-regulated efforts to conserve hearing, and despite the ready availability of hearing protection devices (HPDs), rates of noise-induced hearing loss continue to rise. A recent National Health Interview Survey showed hearing problems among individuals age 45 to 64 up 26 percent over the past 30 years.

HRAL facilities sell a selection of high quality brand name hearing aids and also offer complimentary screening tests, clinical hearing tests, high end ear buds and assistive listening devices. HRAL’s mission is to consolidate the highly fragmented hearing services industry while providing unparalleled service to the estimated 30+ million hearing impaired individuals throughout North America. After a prescription is approved, the independent on-site audiologists and hearing aid practitioners at HearAtLast utilize a refined process to dispense the latest in Name Brand digital hearing aids.

Recently, HRAL announced it will be developing 25 new Hearing Store locations in various markets in the USA and Canada.

**************************************************************

GLW, Corning Inc.

GLW is the world leader in specialty glass and ceramics. Drawing on more than 150 years of materials science and process engineering knowledge, GLW creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences.

GLW was named a 2008 Diamond Supplier for the second consecutive year by Navistar Inc. This award recognizes Navistar’s suppliers for meeting or exceeding Navistar’s performance expectations for quality, delivery, and cost.

GLW was awarded the Institute of Electrical and Electronics Engineers’ (IEEE) prestigious 2009 IEEE Corporate Innovation Recognition. The award recognizes the company’s sustained, outstanding contributions to optical fiber technology and, in particular, the recent development of its highly flexible fiber, Corning® ClearCurve® single-mode optical fiber.

GLW is expected to report second-quarter earnings of 32 cents a share

**************************************************************

Add AMGN, HRAL and GLW to your Watch List!, do your homework, and like always BE READY for the ACTION!

***********Advertisement***********

****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) anticipate being compensated 50,000 free trading shares from a third party for advertising services for HearAtLast Holdings, Inc. HRAL

_______________________________________________________

_______________________________________________________

Dr. Stock Pick is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1000 websites www.crwenews.com, www.stock-ir.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com email: investor@drstockpick.com

 

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com